Rhumbline Advisers Harpoon Therapeutics, Inc. Transaction History

Rhumbline Advisers

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.78 - $5.02 $30,687 - $86,544	-17,240 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$3.54 - $8.08 $8,067 - $18,414	2,279 Added 15.23%	17,240 $86,000
Q3 2021 Nov 12, 2021	BUY	$7.88 - $14.0 $3,159 - $5,614	401 Added 2.75%	14,961 $118,000
Q2 2021 Aug 05, 2021	BUY	$13.81 - $23.25 $58,250 - $98,068	4,218 Added 40.79%	14,560 $202,000
Q1 2021 May 06, 2021	BUY	$17.65 - $24.16 $182,536 - $249,862	10,342 New	10,342 $216,000
Q3 2020 Nov 12, 2020	SELL	$11.01 - $18.52 $111,850 - $188,144	-10,159 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$11.11 - $24.72 $112,866 - $251,130	10,159 New	10,159 $169,000

353K

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.